ProNET: Understanding early risk for psychosis
ProNET: Psychosis-Risk Outcomes Network
['FUNDING_U01'] · YALE UNIVERSITY · NIH-11493636
This project follows people showing early signs of psychosis risk to collect brain scans, EEG, blood tests, speech samples, and phone data that could help predict who develops psychosis.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11493636 on ClinicalTrials.gov |
What this research studies
You would join a large network that follows people judged to be at clinical high risk for psychosis across 26 international sites. Participants complete detailed testing including MRI brain scans, EEG, blood and other body-fluid samples, genetic tests, cognitive and symptom measures, speech recordings, and passive smartphone sensing. These measures are collected repeatedly over a 24-month period with eight clinical visits and biomarker measurements at multiple timepoints, while a group of healthy volunteers provide baseline comparison data. The team also explores real-time phone surveys and novel EEG signals to link daily symptoms and brain changes to longer-term outcomes.
Who could benefit from this research
Good fit: Ideal candidates are people identified as clinical high risk for psychosis (for example, showing attenuated psychotic symptoms) who can attend clinic visits and agree to scans, EEG, blood draws, cognitive testing, and phone-based monitoring.
Not a fit: People without early psychosis symptoms or those unwilling or unable to complete repeated visits, scans, or sample collection are unlikely to directly benefit from participation.
Why it matters
Potential benefit: If successful, this work could help find markers that identify who is most likely to develop psychosis and enable earlier, more personalized preventive care.
How similar studies have performed: Smaller prior CHR studies have identified some promising biomarker signals but findings have been mixed, so this large, multi-site approach is relatively novel and aims to improve reliability.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WOODS, SCOTT W — YALE UNIVERSITY
- Study coordinator: WOODS, SCOTT W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.